Accuray Incorporated stock performance trend indicates that the stock price has rallied 9.78% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -20.72% . Looking at the past 52 week period, the stock price is down -6.13% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Accuray Incorporated has a positive value of 7.28 compared to overall market.Accuray Incorporated is having a Relative Strength Index of 40.67 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Stocks of Accuray Incorporated (NASDAQ:ARAY) rallied by 1% during the past week but lost 9.01% on a 4-week basis. The company has outperformed the S&P 500 by 0.76% in the past week but underperformed the index by 10.05% in the last 4 weeks.
Company shares have received an average consensus rating of Hold for the current week Accuray Incorporated (NASDAQ:ARAY) : On Friday heightened volatility was witnessed in Accuray Incorporated (NASDAQ:ARAY) which led to swings in the share price. The stock opened for trading at $4.95 and hit $5.1 on the upside , eventually ending the session at $5.05, with a gain of 1% or 0.05 points. The heightened volatility saw the trading volume jump to 1,690,595 shares. The 52-week high of the share price is $6.39 and the company has a market cap of $419 million. The 52-week low of the share price is at $4.45 .
Company has reported several Insider transactions to the SEC, on Nov 9, 2015, Joshua Levine (CEO) purchased 50,000 shares at 7.12 per share price.On Sep 1, 2015, Alaleh Nouri (SVP, General Counsel &) sold 957 shares at 6.80 per share price.
Accuray Incorporated Last issued its quarterly earnings results on Jan 31, 2017. The company reported $-0.11 EPS for the quarter, missing the analyst consensus estimate by $ -0.03. Analyst had a consensus of $-0.08. The company had revenue of $87.50 million for the quarter, compared to analysts expectations of $87.00 million. The companys revenue was down -19.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.08 EPS.
ACCURAY INCORPORATED based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 130 systems have been installed in leading hospitals in the Americas, Europe and Asia.